Both bulls and bears can find information in Mindray's (MR)
second quarter report to uphold their preexisting biases about the
stock. Convinced that that growth is slowing and the company is seeing
less margin leverage? There are data to support that. Convinced that
Mindray can continue to exploit a huge market for quality value-priced
medical equipment while generating good free cash flow? We've got you
covered there too.
At a minimum, I'd say Mindray is in that
awkward phase where the company is alienating pure med-tech growth
investors, but not yet attracting the margin/cash flow-driven value/GARP
crowd. Although I think recent ventures into immunoassay and ultrasound
could pay off down the road, I'm not as willing to stick my neck out
right now for a stock like Mindray.
Read more here:
Mindray's Quarter Won't Settle Diddly
No comments:
Post a Comment